药物流行病学杂志
藥物流行病學雜誌
약물류행병학잡지
CHINESE JOURNAL OF PHARMACOEPIDEMIOLOGY
2001年
1期
6-7
,共2页
氯沙坦%贝那普利%高血压
氯沙坦%貝那普利%高血壓
록사탄%패나보리%고혈압
Losartan%Benazepril%Primary hypertension%Randomized controlled study
目的：探讨氯沙坦治疗轻、中度原发性高血压的临床疗效。方法：81例原发性高血压病患者随机分成两组。氯沙坦组(治疗组)：41例，(50～100)mg/d，口服；贝那普利组(对照组)：40例，(10～20)mg/d，口服；疗程均8周。治疗前后做动态血压，肝、肾功能，血糖等检查。结果：治疗组降压总有效率92.7％，对照组90.0％，两组疗效相似，但氯沙坦24 h血压控制优于贝那普利，不良反应前者少于后者。结论：氯沙坦是一种安全、作用持续稳定、耐受性良好、不良反应轻微的治疗轻、中度原发性高血压的新型降压药物之一，值得临床推广应用。
目的：探討氯沙坦治療輕、中度原髮性高血壓的臨床療效。方法：81例原髮性高血壓病患者隨機分成兩組。氯沙坦組(治療組)：41例，(50～100)mg/d，口服；貝那普利組(對照組)：40例，(10～20)mg/d，口服；療程均8週。治療前後做動態血壓，肝、腎功能，血糖等檢查。結果：治療組降壓總有效率92.7％，對照組90.0％，兩組療效相似，但氯沙坦24 h血壓控製優于貝那普利，不良反應前者少于後者。結論：氯沙坦是一種安全、作用持續穩定、耐受性良好、不良反應輕微的治療輕、中度原髮性高血壓的新型降壓藥物之一，值得臨床推廣應用。
목적：탐토록사탄치료경、중도원발성고혈압적림상료효。방법：81례원발성고혈압병환자수궤분성량조。록사탄조(치료조)：41례，(50～100)mg/d，구복；패나보리조(대조조)：40례，(10～20)mg/d，구복；료정균8주。치료전후주동태혈압，간、신공능，혈당등검사。결과：치료조강압총유효솔92.7％，대조조90.0％，량조료효상사，단록사탄24 h혈압공제우우패나보리，불량반응전자소우후자。결론：록사탄시일충안전、작용지속은정、내수성량호、불량반응경미적치료경、중도원발성고혈압적신형강압약물지일，치득림상추엄응용。
To investigate the efficacy and safety of losartan in the treatment of essential hypertension, 81 patients were randomly assigned to two groups. Patients in the first group(n =41) were given losartan 50 mg to 100 mg once a day; those in the second group( n = 40) were given benazepril 10 mg to 20 mg once a day. The treatment course lasted for a weeks. Ambulatory blood pressure, hepatic and renal functions, blood glucose were examined before and after therapy. Our results showed that the total efficacy rate in losartan group was 93％ while that in benazepril group was 90％. The efficacy was similar between the two groups. However, effect of 24 h blood pressure control by lossrtan was superior to than of benazepril. The adverse reaction of losartan was milder that that of benazepril. It is concluded that losartan is a safe, long-acting antihypertensive agent for mild and moderate hypertension with good patient tolerance and less adverse reactions.
